Goldman Sachs Group, Inc. (The) reaffirmed their neutral rating on shares of Smith & Nephew plc (LON:SN) in a research report report published on Monday. Goldman Sachs Group, Inc. (The) currently has a GBX 1,380 ($17.82) price objective on the stock.
A number of other research firms also recently commented on SN. Citigroup Inc. reaffirmed a sell rating and issued a GBX 1,160 ($14.98) price target on shares of Smith & Nephew plc in a research note on Thursday, June 22nd. Jefferies Group LLC boosted their price target on Smith & Nephew plc from GBX 1,350 ($17.44) to GBX 1,515 ($19.57) and gave the company a buy rating in a research note on Friday, July 28th. Deutsche Bank AG reaffirmed a hold rating and issued a GBX 1,200 ($15.50) price target on shares of Smith & Nephew plc in a research note on Friday, July 28th. Credit Suisse Group reaffirmed a neutral rating and issued a GBX 1,280 ($16.53) price target on shares of Smith & Nephew plc in a research note on Friday, July 28th. Finally, Berenberg Bank reaffirmed a hold rating and issued a GBX 1,300 ($16.79) price target on shares of Smith & Nephew plc in a research note on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the stock. Smith & Nephew plc currently has a consensus rating of Hold and an average target price of GBX 1,289.25 ($16.65).
Shares of Smith & Nephew plc (LON SN) traded down 0.14% during midday trading on Monday, hitting GBX 1394.00. 1,836,556 shares of the company were exchanged. The company has a 50-day moving average of GBX 1,359.92 and a 200 day moving average of GBX 1,309.16. The company’s market capitalization is GBX 12.21 billion. Smith & Nephew plc has a one year low of GBX 1,064.91 and a one year high of GBX 1,412.00.
TRADEMARK VIOLATION WARNING: This report was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/2887086/smith-nephew-plc-sn-given-neutral-rating-at-goldman-sachs-group-inc-the.html.
The firm also recently announced a dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Thursday, October 5th will be paid a dividend of $0.12 per share. This represents a yield of 0.72%. The ex-dividend date of this dividend is Thursday, October 5th.
In other news, insider Virginia Bottomley purchased 223 shares of Smith & Nephew plc stock in a transaction dated Wednesday, August 16th. The shares were bought at an average cost of GBX 1,380 ($17.82) per share, for a total transaction of £3,077.40 ($3,974.43).
About Smith & Nephew plc
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.